Walgreens Boots Alliance reached a $683 million settlement with Florida to resolve claims that the pharmacy chain exacerbated an opioid epidemic in the state.

Washington reached a $518 million settlement with drug distributors McKesson Corp., AmerisourceBergen Corp. and Cardinal Health, ending a months-long trial over the companies’ alleged role in fueling the opioid epidemic in the state, the three companies announced on May 3.

Endo International plc announced that the Tennessee Court of Appeals reversed a trial court judge’s order denying a motion for recusal by Endo’s wholly owned subsidiaries Endo Health Solutions Inc. and Endo Pharmaceuticals Inc. in Clay County et al. v. Purdue Pharma, L.P., et al, pending in the Circuit Court for Cumberland County, Tennessee, and remanded the case for transfer to a different judge.

Walgreens Boots Alliance Inc. supplied billions of opioid pills to drug addicts and criminals, contributing to an addiction epidemic in Florida, a lawyer for the state said on April 11 as a civil trial against the pharmacy chain got underway.

West Virginia’s attorney general on April 4 urged a judge to hold Johnson & Johnson, Teva Pharmaceutical Industries Ltd., and AbbVie Inc.’s Allergen liable for causing a “tsunami” of opioid addiction in the state.

Viatris, the drugmaker formerly known as Mylan, agreed to pay $264 million to resolve a class action lawsuit alleging the company engaged in a scheme to delay generic competition to its EpiPen allergy treatment.

Purchasers of Allergan Plc’s Namenda asked a federal judge to approve a $750 million settlement of claims that the drugmaker conspired to keep generic versions of the Alzheimer’s medication off the market.

Bausch Health settled a class action lawsuit for $1.21 billion related to a drop in the drugmaker’s shares during 2013-2015.

Allergan will pay $750 million to settle a class action lawsuit from a group of direct purchasers of the Alzheimer’s disease therapy Namenda in a resolution to the litigation that was set to face trial.

Gilead Sciences has been accused of withholding safer formulations of its HIV drugs in order to maximize profits on those medications that had already been approved, such as Truvada.